论文部分内容阅读
目的：探讨ＣＤ４４Ｖ６及ＥＧＦＲ在卵巢上皮癌中的表达及临床意义。方法： 以 ＳＰ免疫组织化学方法检测 ３３５例卵巢上皮癌， １８例卵巢上皮瘤和 １５例正常卵巢组织石蜡标本 ＣＤ４４Ｖ６及 ＥＧＦＲ的表达，并分析卵巢上皮癌的临床病理资料。结果：①正常卵巢组织 ＣＤ４４Ｖ６及 ＥＧＦＲ均呈阴性表达，卵巢上皮瘤及上皮癌中均有中ＣＤ４４Ｖ６及ＥＧＦＲ表达，正常卵巢与卵巢良恶性肿瘤之间的表达差异有高度显著性（Ｐ＜０．０１），卵巢上皮癌与卵巢上皮瘤之间的表达差异无显著性（Ｐ＞０．０５）；（２）ＣＤ４４Ｖ６及ＥＧＦＲ的阳性表达与卵巢上皮癌的临床分期有关（Ｐ＜０．０５），与组织分化程度及病理类型无关（Ｐ＞０．０５）；③ＣＤ４４Ｖ６及ＥＧＦＲ的阳性表达与卵巢上皮癌预后有关（Ｐ＜０．０５）；④ＣＤ４４Ｖ６及ＥＧＦＲ在卵巢上皮癌中的表达差异无显著性（Ｐ＞０．０５），二者具有相关性（Ｐ＜０．０５）．结论：ＤＤ４４Ｖ６及ＥＧＦＲ可能是卵巢上皮癌发生的相关基因，与肿瘤的发展及转移有关。检测 ＣＤ４４Ｖ６及 ＥＧＦＲ可以估计卵巢上皮癌患者的预后，指导化疗。
Objective: To investigate the expression and clinical significance of CD44V6 and EGFR in epithelial ovarian cancer. Methods: The SP immunohistochemistry was used to detect the expression of CD44V6 and EGFR in 335 cases of epithelial ovarian cancer, 18 cases of ovarian epithelial tumor and 15 cases of normal ovarian tissue. The clinicopathological data of ovarian epithelial carcinoma were analyzed. Results: ① The positive expression of CD44V6 and EGFR in normal ovarian tissue was negative in both ovarian epithelial and epithelial cancers. The expression of CD44V6 and EGFR in normal ovary and ovarian benign and malignant tumors was highly significant (P <0. (P <0.05). (2) The positive expression of CD44V6 and EGFR was correlated with the clinical stage of ovarian epithelial carcinoma (P <0.05) (P> 0.05); ③The positive expression of CD44V6 and EGFR correlated with the prognosis of epithelial ovarian cancer (P <0.05); ④ The expression of CD44V6 and EGFR in ovarian epithelial carcinoma had no significant difference (P> 0.05), the correlation between the two (P <0.05). Conclusion: DD44V6 and EGFR may be the related genes of ovarian epithelial carcinoma, which are related to the development and metastasis of the tumor. Detection of CD44V6 and EGFR can predict the prognosis of patients with epithelial ovarian cancer and guide chemotherapy.